Clinical Trials Directory

Trials / Unknown

UnknownNCT06071923

Effect of Thyroid Disorders in Liver Diseases

Effect of Thyroid Disorders in Metabolic Fatty Liver Changes

Status
Unknown
Phase
Study type
Observational
Enrollment
140 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3. To detect early liver disorders in thyroid disorders using fibroscan .

Detailed description

Non alcoholic fatty liver disease (NAFLD) has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries ,the overall prevalence of NAFLD worldwide was estimated to be 32.4%.prevalence increased significantly over time. considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future.. Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis. In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism. The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH. In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction. Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology

Conditions

Interventions

TypeNameDescription
DEVICEFibroscanScan the liver for metabolic fatty changes

Timeline

Start date
2024-01-01
Primary completion
2025-01-01
Completion
2025-02-01
First posted
2023-10-10
Last updated
2023-10-10

Source: ClinicalTrials.gov record NCT06071923. Inclusion in this directory is not an endorsement.